Previous 10 | Next 10 |
The FDA designates privately held Denovo Biopharma 's lead candidate DB102 (enzastaurin) for Fast Track review for the treatment of newly diagnosed glioblastoma , an aggressive cancer of the brain or spinal cord. More news on: Eli Lilly and Company, MediciNova, Inc., ZIOPHARM Oncology,...
Gainers: Ameri Holdings (NASDAQ: AMRH ) +152% . More news on: Ameri Holdings, Inc., Westwater Resources, Inc., Genius Brands International, Inc., Stocks on the move, , Read more ...
HOUSTON, June 02, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced that the U.S. Food and Drug Administration (FDA) has invited the company to present informati...
HOUSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today announced that a Trial in Progress poster of the ongoing Phase 1/2 clinical trial of seclidemstat i...
Salarius Pharmaceuticals, Inc. (SLRX) Q1 2020 Earnings Conference Call May 14, 2020, 04:30 PM ET Company Participants Jason Rando - EVP & COO, Tiberend Strategic Advisors, Inc., IR David Arthur - President and CEO Mark Rosenblum - CFO Daniela Santiesteban - Director of Busi...
Salarius Pharmaceuticals (NASDAQ: SLRX ): Q1 GAAP EPS of -$0.22 beats by $0.22 . More news on: Salarius Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Seclidemstat Advances Dose Escalation in Phase 1/2 Ewing Sarcoma Clinical Trial; On Track to Report Early Data in 2020 Conference Call and Live Audio Webcast Scheduled for Today, May 14, 2020, at 4:30 p.m. ET HOUSTON, May 14, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc.&...
HOUSTON, May 14, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced today that an abstract on the Phase 1/2 clinical trial of seclidemstat in Ewing sarcoma has bee...
HOUSTON, May 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today announced that the Company will host a conference call and live audio webcast on Thursday, May...
HOUSTON, April 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today announced that its Board of Directors has unveiled nominations and updates to the Board in advanc...
News, Short Squeeze, Breakout and More Instantly...
Salarius Pharmaceuticals Inc. Company Name:
SLRX Stock Symbol:
NASDAQ Market:
Salarius Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.7% to $112.28 on volume of 455,296,152 shares Ford Motor Company (F) fell 18.4% to $11.16 on volume of 256,384,806 shares PROSHARES TRUST (SQQQ) rose 3.4% to $9.37 on volume of 246,885,889 shares Sel...
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) is one of today's top gainers. The company's shares have moved 57.21% on the day to $3.37. Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Secli...
A look at the top 10 most actives in the United States Predictive Oncology Inc. (POAI) rose 115.9% to $2.3099 on volume of 63,737,015 shares Selina Hospitality PLC (SLNA) fell 11.2% to $0.0406 on volume of 59,708,638 shares NVIDIA Corporation (NVDA) fell 1.4% to $112.695 on volume of 52,2...